Neobe Therapeutics Raises $6.8M Seed to Attack Tumor Barriers

Neobe Therapeutics has raised $6.8 million (£5 million) in seed funding to push an engineered-bacteria cancer therapy toward human trials, with an investigational new drug filing targeted for 2028. ARC Ventures led the round. Faber, Macmillan Ventures, Proven Connect and Empirical Ventures participated, alongside existing backer 2048 Ventures. The new money brings Neobe's cumulative funding to more than $10.5 million (£7.9 million).

That is a modest war chest for a program that must still clear preclinical development, manufacturing and regulatory review before a single patient receives a dose. The timeline — roughly three years from seed round to IND filing — assumes the preclinical promise holds under regulatory scrutiny.

What is Neobe actually building?

Founded in 2021 and headquartered in Stevenage, United Kingdom, Neobe is developing programmable bacterial therapies aimed at a stubborn problem in oncology: many patients simply do not respond to existing treatments. One likely reason, according to the company, is the dense, fibrous tissue surrounding some solid tumors. This tumor microenvironment can physically block immune cells and drugs from reaching cancer cells.

Neobe's platform uses genetically engineered, nonpathogenic bacterial strains administered so they travel to tumors and release enzymes that break down components of the surrounding tissue matrix. The goal is not a new cancer drug but an enabler: making tumors more accessible to the immunotherapies and other medicines that already exist. The technology is intended to work alongside current treatments, not replace them.

In plain words: Neobe wants to clear the road so proven drugs can finally arrive.

What did the preclinical data show?

In 2026, Neobe published research in Molecular Cancer Therapeutics conducted with scientists at the University of Cyprus and Barts Cancer Institute in London. The team tested engineered bacteria in a preclinical model of triple-negative breast cancer resistant to a combination of immunotherapy drugs. In one model, a single dose of engineered bacteria enabled complete tumor regression when the same immunotherapy was administered. Subsequent exposure to the same cancer did not produce additional tumors during the observation period, suggesting a possible lasting immune response.

The caveat is large: these results came from preclinical models. It remains uncertain whether comparable outcomes can be achieved safely in human patients.

Who said what?

"Several treatments that can cure cancer already exist, but in far too many patients they simply cannot get to where they are needed," said Dr. Pedro Correa de Sampaio, Co-Founder and CEO of Neobe Therapeutics. "I'm delighted to be working with investors that share our vision of making untreatable cancers curable, and excited to move our platform towards clinical trials."

Joseph Korff, Founder of ARC Ventures, framed the investment in structural terms: "We are excited to back Neobe Therapeutics' differentiated approach to overcoming the physical barriers created by dense tumour matrices. Assets derived from Neobe's platform will improve the efficacy of cancer therapies and extend their benefits to more patients."

Felix Litzkow, Head of Macmillan Ventures — the venture arm of Macmillan Cancer Support — emphasized the access angle: "We are very proud to be supporting Neobe, and to be helping create the right environment for such promising new cancer care solutions to thrive."

Dr. Julie Wolf, Partner at 2048 Ventures, noted her firm has backed Neobe since pre-seed, citing a mission "to make life-saving drugs available and effective for all patients, regardless of the tumour microenvironment."

What happens next?

The seed proceeds will fund additional preclinical studies, manufacturing and development work, and regulatory preparation for the lead program, NEO22. An additional tranche tied to the financing is expected to support the first human clinical trial — a signal that investors have staged their capital against milestones rather than writing one blank check.

Neobe has also appointed Dr. Laura Chow as Chief Medical Officer. She brings immuno-oncology experience and will oversee clinical development strategy as the company prepares for potential first-in-human studies.

If the 2028 filing lands and human data eventually replicate the preclinical results, the approach could expand options for patients whose solid tumors resist current medicines. Until then, the promise rests on mice and a $6.8 million bet that bacteria can do what drugs alone have not.